Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

10.15252/emmm.201505889

Saved in:

Bibliographic Details
Main Authors:	Regula, J.T, Lundh von Leithner, P, Foxton, R, Barathi, V.A, Cheung, C.M.G, Bo Tun, S.B, Wey, Y.S, Iwata, D, Dostalek, M, Moelleken, J, Stubenrauch, K.G, Nogoceke, E, Widmer, G, Strassburger, P, Koss, M.J, Klein, C, Shima, D.T, Hartmann, G
Other Authors:	OPHTHALMOLOGY
Format:	Article
Published:	2020
Subjects:	angiopoietin 2 CD16 antigen monoclonal antibody rg 7716 unclassified drug vasculotropin A vasculotropin A antibody vasculotropin antibody immunologic factor angiogenesis animal experiment animal model Article binding site cross reaction drug clearance drug efficacy drug potency drug protein binding eye disease human monotherapy mouse nonhuman priority journal protein depletion protein targeting retina edema retina vasculitis subretinal neovascularization upregulation vitreous body animal antagonists and inhibitors disease model Eye Diseases isolation and purification Macaca fascicularis Neovascularization, Pathologic pathology preclinical study treatment outcome Angiopoietin-2 Animals Antibodies, Monoclonal Disease Models, Animal Drug Evaluation, Preclinical Immunologic Factors Treatment Outcome Vascular Endothelial Growth Factor A
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/179906
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Be the first to leave a comment!